Dxcover is a clinical stage liquid biopsy company that focuses on the early detection of multiple cancers for more effective treatment outcomes. Using infrared spectroscopy of circulating pan-omic biomarkers, the company has pioneered the early detection and identification of cancer, with compelling clinical data showcasing high accuracy detection of Stage I and Stage II cancers. Founded in 2016 and based in Scotland, United Kingdom, Dxcover is expanding its operations to the USA. The company secured a significant £7.50M Series A investment on 01 February 2023, with backing from notable investors including SIS Ventures, Scottish Enterprise, Eos, Mercia Fund Managers, Mark Bamforth, Norcliffe Capital, and University of Strathclyde.
Dxcover
The Future of Cancer Diagnostics
Founded 2016
24 employees
Series A
Total: $14.40M
Biotechnology, Health Care +1
General Information
Company Name
Dxcover
Founded Year
2016
Founders / Decision Makers
Employees
24
Industries
Biotechnology, Health Care, Machine Learning
Funding Stage
Series A
BounceWatch is an independent company data service, not affiliated with Dxcover. To contact Dxcover, visit dxcover.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
Discover More
Biotechnology
About Dxcover
Taxonomy: Liquid biopsy, Cancer diagnostics, Early detection, Infrared spectroscopy, Clinical stage, Biomarkers, Scotland, USA, Biotech, Oncology, Medical technology
Funding Rounds & Investors (6)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series A | £7.50M | 7 |
|
01 Feb 2023 |
| Grant | £2.20M | 1 |
|
21 Dec 2022 |
| Seed Round | £1.10M | 3 |
|
04 Mar 2021 |
| Seed Round | £2.40M | 5 |
|
07 Sep 2020 |
| Seed Round | £1.20M | 2 |
Scottish Investment Bank, Mercia Fund Managers
|
02 May 2019 |
| Grant | Undisclosed | 2 |
|
11 Feb 2019 |
Dxcover Alternatives & Competitors
Dxcover vs
Dxcover vs
Pioneering Life-Saving Cancer Detection with Advanced Liquid Biopsy Solutions
Venture round
Biotechnology, Health Care
Dxcover vs
Savicell
Israel
THE IMMUNOBIOPSY™ COMPANY – BECAUSE EARLY DETECTION IS LIFE™
7 employees
Biotechnology, Health Care
FAQ About Dxcover
The Future of Cancer Diagnostics
Dxcover was founded in 2016.
Dxcover operates in Biotechnology, Health Care and Machine Learning. Its work centres on Liquid biopsy, Cancer diagnostics, Early detection and Infrared spectroscopy.
Dxcover has approximately 24 employees.
Dxcover has completed 6 funding rounds, raising a total of $14.40M. The latest funding stage is Series A.
Top alternatives and competitors to Dxcover include Elypta, Thrive Earlier Detection, Savicell, Micronoma, VisionGate, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Dxcover and Elypta are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for Dxcover, https://bouncewatch.com/company/dxcover, updated 10 October 2024. When citing, please name BounceWatch and link this page.
